{"slug": "today-in-nature-methods-we-shared-research-on-how-ai-can-help-us-better-cell-new", "title": "Today in Nature Methods, we shared research on how AI can help us better understand cell behavior, offering new insights into why cancer medicines do not work the same for everyone.", "summary": "Researchers published a study in Nature Methods demonstrating how AI can analyze individual cancer cell behavior, offering insights into why cancer drugs work differently across patients. The approach moves beyond static mutation-based classification to understand dynamic cell states, potentially enabling more precise, personalized therapies.", "body_md": "Today in Nature Methods, we shared research on how AI can help us better understand cell behavior, offering new insights into why cancer medicines do not work the same for everyone.\nBy learning more about cell state — how individual cancer cells respond to their surroundings — we have the potential to match therapies more precisely to each patient and improve outcomes.\nRead more: [https://lnkd.in/gtK-zy_X](https://www.linkedin.com/redir/redirect?url=https%3A%2F%2Flnkd%2Ein%2FgtK-zy_X&urlhash=W2a-&trk=public_post-text)\n\n\"Decoding the incredibly complex system of cellular behavior is where AI truly shows its transformational power. Shifting from a 'one-size-fits-all' approach to highly personalized, data-driven therapies will completely redefine the future of medicine. It is deeply inspiring to see technology solving such foundational biological challenges!\"\n\n[Andre Watts](https://www.linkedin.com/in/andre-watts-a0a076321?trk=public_post_comment_actor-name)5d\n\nThis is one of the most important signals in the AI era because it points to a deeper truth: complex systems cannot be understood by labels alone. Cancer treatment has become more precise by moving from where the disease appears in the body, to the mutations inside the cell. But this research points to the next layer: state, behavior, environment, adaptation, resistance, and response. That matters because two things can look similar on paper and behave completely differently under pressure. A tumor is not only its diagnosis. A cell is not only its mutation. A patient is not only a category. The real question is: what is the system doing, how is it changing, what is it responding to, and what signals are being missed by the tools we currently trust?\n\nWhat stands out is that this isn’t really a story about AI. It’s a story about reducing uncertainty. For decades medicine often had to rely on averages.The more we understand individual cell behavior, the more treatment can move from population-level assumptions to patient-level decisions.That’s a powerful shift.\n\n[Dominik Bösl](https://de.linkedin.com/in/boesl?trk=public_post_comment_actor-name)5d\n\n[Satya](https://www.linkedin.com/in/satyanadella?trk=public_post_comment-text), most readers will take precision oncology as the headline. The quietly radical line sits underneath: the team reports these models learn more from a wide range of cell states than from being fed more data of the same kind. In a field that spent three years assuming scale alone would carry it, that is the genuinely new claim.\nIt matters because the bottleneck was never only categorising tumours by mutation - it was that a cancer cell behaves differently in a dish than in a patient. Crawford's pancreatic example is telling: cultured cells often collapse into a single state, so the lab stops representing the disease it should model. An AI trained on that narrowness inherits the blind spot, however large the dataset.\nWhich is where I would push, in the friendliest way. Cell state is a moving target, shaped by the very microenvironment we strip away to measure it. The clinical question is not whether a model can label states, but whether those labels stay stable from ex vivo to in vivo to the patient in front of an oncologist. Diverse data only helps if it is the right diversity.\nThe move from targeting a mutation to shifting a state is the part to be hopeful about.\n\n[Dario D.](https://hr.linkedin.com/in/dario-d-82b389372?trk=public_post_comment_actor-name)5d\n\nThis is an important direction. The key shift here is state. Cancer treatment cannot depend only on static classification or isolated mutation data if the real behavior of cells changes across environment, time, and patient context. That same principle applies more broadly to AI systems entering medicine. The model can help detect patterns, but the system around it must preserve: cell state, patient context, evidence lineage, clinical validation, auditability, human medical authority, and accountability across time. In healthcare, intelligence is not only prediction. It is governed interpretation connected to real human outcomes. The future of AI in medicine will not be defined only by stronger models, but by systems that can understand changing biological state while keeping doctors, patients, evidence, and responsibility inside the loop. Node-0 Me & Spok ✌️\n\nThe reason cancer medicines don't work the same for everyone is the same reason leadership interventions don't work the same for every executive: the surface diagnosis is never the whole picture. Cell state — how a cell responds to its environment, adapts under pressure, and resists intervention — is a biological parallel to what I observe in high-performing leaders. The ones who plateau aren't lacking intelligence or drive. They're operating from a fixed internal state that hasn't adapted to the complexity they're now carrying. This research is bigger than oncology. It's a framework for understanding why any complex system — biological or human — responds differently to the same input.\n\nThe reason cancer medicines don’t work the same for everyone comes down to the incredible complexity and adaptability of cancer itself. Cancer is not a single disease, but a broad category of diseases characterized by uncontrolled cell growth - and every patient's cancer is uniquely their own. The paradigm shift will happen when we start viewing the human body as a highly coherent, energy-optimized information network. Precision oncology - matching treatments to the specific molecular profile of a patient's tumor by understanding vibronics and topological behavior of cells will help us understand the orchestration of the human body in ways that will unlock medical advancements. I think I speak on behalf of everyone who has lost someone they loved to cancer - thank you for your work and research in curing this terrible disease.\n\nWhat stands out to me is the shift from looking at cancer as a static thing to looking at it as a state dependent process. For years we have tended to classify, label, and segment. What AI is beginning to reveal is that behavior often emerges from context, relationships, and changing conditions rather than from the label alone. The interesting question may not be: \"What kind of cell is this?\" But: \"What state is this cell currently in, and what pressures caused that state to emerge?\" That feels like a much broader pattern showing up across biology, organizations, economies, and even human behavior. The label matters. The state may matter more.\n\n[Gaurav Kumar](https://in.linkedin.com/in/gkarora00786?trk=public_post_comment_actor-name)5d\n\nA brilliant diagnostic of the future of precision medicine, Satya! Applying a standardized approach to complex cancer treatments is a deeply 'symptomatic' trap that introduces severe 'operational friction' into patient recovery. When therapies fail because unique cellular states are ignored, it creates a massive 'systemic bottleneck' in global healthcare. Leveraging AI to map these behaviors is pure 'preventive diagnostics.' It perfectly executes the core philosophy we champion: 'Preventive health ka matlab — problem se pehle check, treatment se pehle action.' By proactively matching the therapy to the precise cellular environment before administration, Microsoft is building the exact 'root-cause infrastructure' modern oncology needs. Establishing this frictionless 'operational baseline' of personalized care is exactly how true, scalable healing is achieved. Exceptional breakthrough!\n\nUnderstanding cell behavior is only part of the challenge. The next challenge is ensuring those insights translate into consistent clinical decisions across patients, teams, and treatment pathways. At scale, variation in decision execution can become as significant as variation in biology. Execution depends on decision architecture.\n\n[See more comments](https://www.linkedin.com/signup/cold-join?session_redirect=https%3A%2F%2Fwww%2Elinkedin%2Ecom%2Fposts%2Fsatyanadella_why-dont-cancer-medicines-work-the-same-activity-7470160151099006976-w-EO&trk=public_post_see-more-comments)", "url": "https://wpnews.pro/news/today-in-nature-methods-we-shared-research-on-how-ai-can-help-us-better-cell-new", "canonical_source": "https://www.linkedin.com/feed/update/urn:li:activity:7470160151099006976/", "published_at": "2026-06-10 13:40:12+00:00", "updated_at": "2026-06-15 14:13:05.265149+00:00", "lang": "en", "topics": ["artificial-intelligence", "ai-research", "ai-products"], "entities": ["Nature Methods", "Andre Watts", "Dominik Bösl", "Satya Nadella", "Dario D."], "alternates": {"html": "https://wpnews.pro/news/today-in-nature-methods-we-shared-research-on-how-ai-can-help-us-better-cell-new", "markdown": "https://wpnews.pro/news/today-in-nature-methods-we-shared-research-on-how-ai-can-help-us-better-cell-new.md", "text": "https://wpnews.pro/news/today-in-nature-methods-we-shared-research-on-how-ai-can-help-us-better-cell-new.txt", "jsonld": "https://wpnews.pro/news/today-in-nature-methods-we-shared-research-on-how-ai-can-help-us-better-cell-new.jsonld"}}